Stayble has now enrolled and treated the first patient in the company's clinical phase Ib study with STA363 for the treatment of herniated discs. This milestone marks a continued positive development for the drug candidate STA363, which is already undergoing a phase IIb study for degenerative disc disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.266 SEK | -5.67% | +5.14% | -12.21% |
1st Jan change | Capi. | |
---|---|---|
-12.21% | 8L | |
+18.72% | 12TCr | |
+14.19% | 11TCr | |
-4.93% | 2.42TCr | |
+3.23% | 2.28TCr | |
-10.44% | 1.8TCr | |
-41.74% | 1.64TCr | |
-13.31% | 1.64TCr | |
+2.44% | 1.36TCr | |
+27.89% | 1.17TCr |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Enters the First Patient in Herniated Disc Study